A recent study by Monash University reveals that beta blockers, commonly used for blood pressure, may offer protection against triple-negative breast cancer. Researchers discovered that these drugs can switch off the HOXC12 gene, slowing the disease’s progression. This breakthrough could help identify patients most likely to benefit from beta-blocker therapy, potentially offering a low-cost treatment option for this aggressive cancer. Post navigation Asia Cup: How Jitesh Sharma kept the competition at bay Income-tax Act 2025: No new taxes introduced; will be effective from next year
